Novel Compounds as LPAR1 Inhibitors for Treating Systemic Sclerosis

Provided herein are novel compounds as LPAR1 inhibitors, pharmaceutical compositions, use of such compounds in treating systemic sclerosis, and processes for preparing such compounds.

Authors

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2026-01-02
DOI
https://doi.org/10.1021/acsmedchemlett.5c00764
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel Compounds as LPAR1 Inhibitors for Treating Systemic Sclerosis

Ram W. Sabnis
ACS Medicinal Chemistry Letters
Systemic Sclerosis and Related Diseases
article

Novel Compounds as LPAR1 Inhibitors for Treating Systemic Sclerosis

Ram W. Sabnis
article en

Abstract

Provided herein are novel compounds as LPAR1 inhibitors, pharmaceutical compositions, use of such compounds in treating systemic sclerosis, and processes for preparing such compounds.

ACS Medicinal Chemistry LettersVol. 17(2)
Openalex Percentile: Top 99%
Systemic Sclerosis and Related Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Novel Compounds as LPAR1 Inhibitors for Treating Systemic Sclerosis — Ram W. Sabnis · ACS Medicinal Chemistry Letters (2026) | TGRS Research Map | TGRS